Vaxart Granted Extension by Nasdaq to Regain Compliance

- Company must regain compliance with the Nasdaq Bid Price Rule on or before the October 17, 2025 deadline -

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it received a decision letter (the “Letter”) from the Nasdaq Hearings Panel (the “Panel”) on August 27, 2025, granting the Company’s request to effect a plan to regain compliance with The Nasdaq Stock Market’s LLC (“Nasdaq’s”) minimum bid price requirement.

Read more at globenewswire.com